Masahiro Hatooka, Tomokazu Kawaoka, Hiroshi Aikata, Fumi Honda, Yuki Nakamura, Norihito Nakano, Kei Morio, Takayuki Fukuhara, Tomoki Kobayashi, Yuko Nagaoki, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Kazuo Awai, Kazuaki Chayama
To assess the outcome of stable disease (SD) patients with advanced hepatocellular carcinoma (HCC) by tumor markers after the first course of hepatic arterial infusion chemotherapy (HAIC). The study subjects were 156 HCC patients treated with HAIC and classified as Child Pugh A, with no extrahepatic metastasis, and no history of sorafenib treatment. In the study and validation cohorts, the AFP and DCP ratios of patients who were considered SD to the first course of HAIC were analyzed by AUROC for a prediction of response to the second course of HAIC...
September 2016: Hiroshima Journal of Medical Sciences